Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications

Sposito, Marco; Eccher, Serena; Pasqualin, Luca; Scaglione, Ilaria Mariangela; Avancini, Alice; Tregnago, Daniela; Trestini, Ilaria; Insolda, Jessica; Bonato, Adele; Ugel, Stefano; Derosa, Lisa; Milella, Michele; Pilotto, Sara; Belluomini, Lorenzo

doi:10.1080/1744666x.2024.2372327

Expert Review of Clinical Immunology

2024

DOI: 10.1080/1744666x.2024.2372327

|View full text |Cite

Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications

Marco Sposito,

Serena Eccher,

Luca Pasqualin

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges

Ye,

Yu,

Guo

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Lung cancer, the leading cause of death worldwide, is associated with the highest morbidity. Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung cancer cases. Advances in the domain of cancer treatment have improved the prognosis and quality of life of patients with metastatic NSCLC. Nevertheless, tumor progression or metastasis owing to treatment failure caused by primary or secondary drug resistance remains the cause of death in the majority of cases. Epithelial–mesenchymal transition (EMT), a vital biological process wherein epithelial cancer cells lose their inherent adhesion and transform into more invasive mesenchymal-like cells, acts as a powerful engine driving tumor metastasis. EMT can also induce immunosuppression in the tumor environment, thereby promoting cancer development and poor prognosis among patients with NSCLC. This review aims to elucidate the effect of EMT on metastasis and the tumor immune microenvironment. Furthermore, it explores the possible roles of EMT inhibition in improving the treatment efficacy of NSCLC. Targeting EMT may be an ideal mechanism to inhibit tumor growth and progression at multiple steps.

show abstract

Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges

Ye,

Yu,

Guo

et al. 2024

Biomolecules

View full text Add to dashboard Cite

show abstract

The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment—Literature Review

Gorzelak-Magiera,

Domagała-Haduch,

Kabut

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related morbidity and mortality. The median survival time for patients with advanced non-small-cell lung cancer before the era of molecular-based personalized treatment was 7.9 months. The discovery of predictive factors and the introduction of molecular diagnostics into daily practice made a breakthrough, enabling several years of survival in patients with advanced disease. The discovery of rearrangements in the ALK gene and ALK tyrosine kinase inhibitors has resulted in a dramatic improvement in the prognosis of patients with this subtype of cancer. Currently, three generations of ALK inhibitors differing in activity, toxicity and degree of penetration into the central nervous system are available in clinical practice. The current state of knowledge on ALK inhibitors used in clinical practice is summarised in this research paper. Methods of diagnosis of abnormalities in ALK have been shown, and the review of research that contributed to the development of the next generation of ALK inhibitors has been presented.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications

Cited by 2 publications

References 95 publications

Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges

Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges

The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment—Literature Review

Contact Info

Product

Resources

About